{"id":20068,"date":"2026-06-12T04:15:00","date_gmt":"2026-06-12T02:15:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=1f790c9a3e40ccd29cd3eb1bc1d2ddd3"},"modified":"2026-06-12T04:15:00","modified_gmt":"2026-06-12T02:15:00","slug":"rosen-law-firm-urges-erasca-inc-nasdaq-eras-stockholders-with-large-losses-to-contact-the-firm-for-information-about-their-rights","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=20068","title":{"rendered":"Rosen Law Firm Urges Erasca, Inc. (NASDAQ: ERAS) Stockholders with Large Losses to Contact the Firm for Information About Their Rights"},"content":{"rendered":"<p class=\"bwalignl\">NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the \u201cClass Period\u201d). Erasca develops oncology therapies.<\/p><p class=\"bwalignl\">\nFor more information, submit a <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frosenlegal.com%2Fcases%2Ferasca-inc%2Fjoin&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=form&amp;index=1&amp;md5=04e0c468470f62a93d0083e6c72f9446\" rel=\"nofollow\" shape=\"rect\">form<\/a>, <a  href=\"mailto:case@rosenlegal.com\" rel=\"nofollow\" shape=\"rect\">email<\/a> attorney Phillip Kim, or give us a call at 866-767-3653.<\/p><p class=\"bwalignl\">\nThe Allegations: Rosen Law Firm is Investigating the Allegations that Erasca, Inc. (NASDAQ: ERAS) Misled Investors Regarding its Business Operations.<\/p><p class=\"bwalignl\">\nAccording to the lawsuit, Erasca, Inc., along with its CEO and CFO, violated federal securities laws by making false and misleading statements about its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential \u201cbest-in-class\u201d therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines\u2019 competing drug candidate, RMC-6236, while failing to disclose that those comparisons were allegedly improper, exposed Erasca to patent and trade secret disputes, and lacked a reasonable basis.<\/p><p class=\"bwalignl\">\nWhen the true details entered the market, the lawsuit claims that investors suffered damages.<\/p><p class=\"bwalignl\">\nWhat Now: You may be eligible to participate in the class action against Erasca, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 10, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frosenlegal.com%2Fcases%2Ferasca-inc&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=dae0a329835d5d92b49432091a12690e\" rel=\"nofollow\" shape=\"rect\">here<\/a>.<\/p><p class=\"bwalignl\">\nAll representation is on a contingency fee basis. Shareholders pay no fees or expenses.<\/p><p class=\"bwalignl\">\nAbout Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rosenlegal.com%2F&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=Rosen+Law+Firm&amp;index=3&amp;md5=50b8a70d5c6b1f86441b9732c5ea329a\" rel=\"nofollow\" shape=\"rect\">Rosen Law Firm<\/a> is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders.<\/p><p class=\"bwalignl\">\nFollow us for updates on LinkedIn: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fthe-rosen-law-firm&amp;index=4&amp;md5=b71a35e2019e2f3e4fa9536b1e79352c\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=https%3A%2F%2Ftwitter.com%2Frosen_firm&amp;index=5&amp;md5=548c125a45aabd9232742f592c9043ad\" rel=\"nofollow\" shape=\"rect\">https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.facebook.com%2Frosenlawfirm%2F&amp;index=6&amp;md5=8981bf26db2e3883433aa0833eb741a0\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p><p class=\"bwalignl\">\nAttorney Advertising. Prior results do not guarantee a similar outcome.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260611947764\/en\/1164042\/5\/July_30%2C_2021_-_ROSEN_LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260611947764\/en\/1164042\/22\/July_30%2C_2021_-_ROSEN_LOGO.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260611947764\/en\/1164042\/5\/July_30%2C_2021_-_ROSEN_LOGO.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260611947764\/en\/1164042\/21\/July_30%2C_2021_-_ROSEN_LOGO.jpg\" \/><\/a><br\/> <b>Contacts<\/b> <br\/><p class=\"bwalignl\">\nLaurence Rosen, Esq.\n<br\/>Phillip Kim, Esq.\n<br\/>The Rosen Law Firm, P.A.\n<br\/>275 Madison Avenue, 40th Floor\n<br\/>New York, NY 10016\n<br\/>Tel: (212) 686-1060\n<br\/>Toll Free: (866) 767-3653\n<br\/>Fax: (212) 202-3827\n<br\/><a  href=\"mailto:case@rosenlegal.com\" rel=\"nofollow\" shape=\"rect\">case@rosenlegal.com<\/a><br\/><a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.rosenlegal.com&amp;esheet=54552472&amp;newsitemid=20260611947764&amp;lan=en-US&amp;anchor=www.rosenlegal.com&amp;index=7&amp;md5=6364700208447f83a65868b6605b9177\" rel=\"nofollow\" shape=\"rect\">www.rosenlegal.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>NEW YORK&#8211;(BUSINESS WIRE)&#8211;Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the \u201cClass Per&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20068","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20068"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20068\/revisions"}],"predecessor-version":[{"id":20069,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20068\/revisions\/20069"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20068"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20068"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}